-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), showed a downward trend in the overall mortality rate of lung cancer in the United States, but the impact of lung cancer subsypes on mortality trends has not been sufficiently studied.
SEER study, the researchers assessed trends in mortality in specific lung cancer patients in the United States, and also analyzed lung cancer morbidity and survival rates based on lung cancer subtypes, and assessed changes in morbidity and morbidity-based mortality rates among different types of lung cancer through the Mainpoint system.
the mortality rate of NSCLC patients showed a rapid decline, which exceeded the decrease of morbidity, and the decrease of mortality rate in NSCLC patients was associated with a significant increase in survival rate, with targeted therapy as the decisive factor.
in the male population, the mortality rate for NSCLC fell by 6.3 per cent per year in 2013-16 and by 3.1 per cent per year in 2008-16.
the specific survival rate of male patients with NSCLC increased from 26% in 2001 to 35% in 2014.
NSCLC mortality rates declined significantly among all racial and ethnic groups.
mortality rate declined in female NSCLC patients at the same rate as in men.
Unlike NSCLC, the mortality rate of non-small cell lung cancer, morbidity and survival rate change SCLC patient mortality rate decreased by the same amount as the morbidity rate, the survival rate of patients did not improve significantly, of which the limited progress of SCLC treatment is the most important factor.
, morbidity and survival rates of small cell lung cancer decreased significantly in 2013-2016, and survival rates in non-small cell lung cancer patients in the United States increased significantly.
with the progress of treatment, the decrease of morbidity, especially the widespread use of targeted therapy, is an important factor in the decline of mortality in patients with non-small cell lung cancer.
.
